Figure 2.

Fc‐engineered anti‐CD25 variants differentially impact regulatory T (Treg) cells in vivo. (a–d) B6 wild‐type and Fcer1g ^−/− mice were given a single dose of PC61‐mIgG1^(N297Q), PC61‐mIgG2a or vehicle control and killed 7 days post‐injection for flow cytometric analysis of splenocytes. (a) Representative dot plots gated on Foxp3⁺ cells that are either CD25⁺ or CD25^low/− within a CD3⁺ CD4⁺ gate. (B) Distribution of CD25⁺ Treg cells and CD25^low/− Treg cells within the Foxp3⁺ population (mean). (C) Absolute number of Foxp3⁺ cells (mean ± SD). (D) Percentage of Foxp3⁺ cells within the CD3⁺ CD4⁺ gate (mean ± SD). Data are representative of three (a–d) independent experiments. *P < 0·05; ns, not significant.